// App-Quantinova.ai

: Cost-Effectiveness of Second-Line Therapies in Adult Patients with Chronic Immune Thrombocytopenia

Researchers

Presenter

  • George Goshua

Principal Investigators

  • Pranay Sinha

  • Lauren Pischel

  • Alfred Ian Lee

  • Adam Cuker

Medical Centers

  • Section of Hematology, Yale University School of Medicine, New Haven, CT

  • Section of Infectious Diseases, Boston Medical Center, Boston, MA

  • Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Hamden, CT

  • Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT

  • Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT

  • Department of Medicine and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA

  • Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Infectious Diseases (ID)

Disease

  • Immune thrombocytopenia

  • Venous thrombosis

  • Septic shock

  • Sepsis

Biomarkers

  • N/A

Drug/Treatment

  • Eltrombopag

  • Romiplostim

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved